PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-65.74%
Both yoy net incomes decline, with TRVN at -45.68%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-40.21%
Negative yoy D&A while TRVN is 3.71%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
147.42%
Well above TRVN's 66.31% if it’s a large positive yoy. Michael Burry would see a bigger future tax burden vs. competitor’s approach.
-33.50%
Negative yoy SBC while TRVN is 21.09%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
2171.95%
Well above TRVN's 175.64% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
577.15%
AP growth of 577.15% while TRVN is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-447.03%
Negative yoy usage while TRVN is 175.64%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-33.50%
Negative yoy while TRVN is 57.82%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-13.29%
Negative yoy CFO while TRVN is 0.79%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
19.79%
Some CapEx rise while TRVN is negative at -302.91%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
19.79%
Lower net investing outflow yoy vs. TRVN's 104.74%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
-207.32%
Both yoy lines negative, with TRVN at -1.70%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
104.75%
We slightly raise equity while TRVN is negative at -100.27%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.